Literature DB >> 1424122

Immunoluminometric assay of chromogranin A in serum with commercially available reagents.

H Bender1, A Maier, B Wiedenmann, D T O'Connor, K Messner, H Schmidt-Gayk.   

Abstract

Chromogranin A (Cg A) is a useful marker of neuroendocrine neoplasia in humans. Here we describe an immunoluminometric assay (ILMA) for measuring Cg A in serum, with use of a new tube as a solid phase. The new tube has a large surface area and is coated with a polyclonal antibody. Optimized coating conditions provide a high IgG adsorption to the polystyrene wall. Serum is added to the coated tube and incubated for 2 h or overnight. After washing the tubes, acridinium ester-labeled monoclonal antibody against Cg A is added and incubation is continued for 2 h. The tubes are washed again and the bound luminescence is measured. The assay is very sensitive (detection limit 1 microgram/L, if 25 microL of serum is used), is specific for human Cg A, and offers a wide dynamic range (1-1000 micrograms/L). The range in healthy humans is 10-53 micrograms/L (median 30 micrograms/L). The correlation of serum Cg A to creatinine and parathyroid hormone is described. We also report the influence of intravenous calcium injection on Cg A concentrations in serum.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1424122

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  4 in total

1.  Doxorubicin and streptozotocin after failed biotherapy of neuroendocrine tumors.

Authors:  Marianne E Pavel; Ulrich Baum; Eckhart G Hahn; Johannes Hensen
Journal:  Int J Gastrointest Cancer       Date:  2005

2.  Adrenal incidentaloma diagnosed as pheochromocytoma by plasma chromogranin A and plasma metanephrines.

Authors:  K Miehle; J Kratzsch; J W M Lenders; R Kluge; R Paschke; C A Koch
Journal:  J Endocrinol Invest       Date:  2005-12       Impact factor: 4.256

3.  The long-acting somatostatin analogue octreotide alleviates symptoms by reducing posttranslational conversion of prepro-glucagon to glucagon in a patient with malignant glucagonoma, but does not prevent tumor growth.

Authors:  F Jockenhövel; S Lederbogen; T Olbricht; H Schmidt-Gayk; E P Krenning; S W Lamberts; D Reinwein
Journal:  Clin Investig       Date:  1994-01

4.  A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours.

Authors:  G P Bernini; A Moretti; M Ferdeghini; S Ricci; C Letizia; E D'Erasmo; G F Argenio; A Salvetti
Journal:  Br J Cancer       Date:  2001-03-02       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.